We have previously demonstrated that a functional dopamine D2 receptor promoter variant (DRD2 À141 Ins/Del) predicts response to nicotine replacement therapy (NRT). The present study extends this finding in the same population of 363 NRT-treated subjects, by examining variation in the gene encoding the neuronal calcium sensor-1 protein (FREQ), which functions to regulate D2 receptor desensitization. The results indicate a statistically significant interaction effect of DRD2À141 and FREQ genotypes on abstinence at the end of the NRT treatment phase; 62% of the smokers with at least one copy of the DRD2 À141 Del allele and two copies of the FREQ rs1054879 A allele were abstinent from smoking, compared to 29-38% abstinence rates for other smokers in the trial. This result suggests that the interaction between variation in the DRD2 and FREQ genes, which both encode components of the D2 dopamine receptor signal transduction pathway, impacts the efficacy of NRT.
Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence There are six FDA-approved medications for the treatment of nicotine dependence, including the various forms of nicotine replacement therapy (NRT) and bupropion. 1 Yet, the majority of smokers are unable to quit smoking and maintain abstinence with these medications. 2, 3 Although a considerable amount of data from both open-label and placebo-controlled clinical trials support the efficacy of NRT and bupropion in the treatment of nicotine dependence, there is a great deal of variability in how patients respond to each of these treatments (reviewed by Lerman et al. 4 ). Previously, we examined the role of two putative functional variations in the DRD2 gene, À141 Ins/Del and C957T, in the therapeutic outcomes of bupropion and NRT treatment for nicotine dependence. 5 Our findings indicate that smokers homozygous for the DRD2 À141 Ins benefit more from bupropion treatment and persons with Ins/Del or Del/ Del genotypes at the DRD2À141 locus respond better to behavioral counseling or NRT. 5 Results from this study and others [6] [7] [8] may, in the future, help practitioners maximize the therapeutic benefit of pharmacological treatments for nicotine dependence.
Although most pharmacogenetic studies of the dopaminergic neurotransmitter system in nicotine dependence have focused on genes encoding dopamine G-proteincoupled receptors (GPCRs) or genes encoding dopaminemetabolizing enzymes, dopaminergic neurotransmission is not solely dependent on these components of dopaminemediated signal transduction pathways. During the past several decades, advancements in proteomic-and yeast twohybrid-based methods have given rise to a growing list of intracellular GPCR interacting proteins (GIPs) (reviewed by Bockaert et al. 9 ). Studies show that GIPs regulate key aspects of GPCR signaling, including receptor trafficking and effector coupling. 9 Based on their ability to regulate signaling through dopamine receptors, it has recently been postulated that dopamine receptor interacting proteins (DRIPs) may contribute to the pathology and/or treatment of psychiatric disorders. 10 One DRIP of particular relevance to the biology of addiction disorders is neuronal calcium sensor-1 (NCS-1). NCS-1 is an evolutionarily conserved EF hand calcium binding protein involved in the regulation of a wide variety of neuronal functions including membrane traffic, cell survival, and ion channel and receptor signaling (reviewed by Burgoyne et al. 11 ). In mammalian cells, NCS-1 has been shown to promote exocytosis from dense core vesicles of neuroendocrine cells and plays a prominent role in D2 dopamine receptor desensitization via a direct interaction with the receptor. 12 Given the established role for NCS-1 in regulating D2 receptor signaling, these studies present the intriguing possibility that alterations in NCS-1 activity and/ or expression may contribute to the dopaminergic pathophysiology of nicotine dependence and response to nicotine replacement medications.
In this brief report, we extend our previous finding that genetic variation in a component of the dopaminergic signaling pathway, the D2 dopamine receptor, may be useful in predicting the response to pharmacological treatments for nicotine dependence. DNA samples from participants in the bupropion and NRT trials were genotyped for two SNPs in the gene encoding the NCS-1 protein (FREQ) to determine if variation in genes encoding multiple components of the dopaminergic signal transduction pathway could have additional value in predicting therapeutic response. Here, we report a novel finding from the open-label randomized trial comparing nicotine nasal spray (NS) and transdermal nicotine (TN).
Results

Descriptive data
Of the 363 participants included in the analyses, 53% were male, 50% were college graduates, and the mean age was For the FREQ rs3780715 SNP, 100 (27%) participants were homozygous for the A allele (AA), 181 (50%) were heterozygous (AG), and 82 (23%) were homozygous for the G allele (GG). For the FREQ rs1054879 SNP, 111 (31%) participants were homozygous for the A allele (AA), 164 (45%) were heterozygous (AG), and 88 (24%) were homozygous for the G allele (GG). The D 0 estimate for these two SNPs is 0.22. For the À141C Ins/Del SNP, 293 (81%) participants were homozygous for the C allele (CC), 67 (18%) were heterozygous (CN), and three (1%) were homozygous for the N allele (NN).
A total of 176 (48%) participants were randomized to the TN condition and 187 (52%) to the NS condition. There were no significant differences between the treatment groups on genotype or other baseline variables, with the exception of a trend for a sex difference (58% male in TN group, 49% male in NS group; Pearson w 2 (1) ¼ 3.54,
Of the 363 eligible participants, 344 (95%) provided data at end of treatment (EOT) and 347 (96%) provided data at 6-month follow-up. Compared to participants lost to followup at EOT, those who provided data at EOT had marginally higher educational levels (Mantel-Haenszel w 2 (1) ¼ 3.36, P ¼ 0.067) and were more likely to have two A alleles at the FREQ rs3780715 SNP (Mantel-Haenszel w 2 (1) ¼ 3.92, P ¼ 0.048). Compared to participants lost to follow-up at 6 months, those who provided data at 6 months were more likely to be in the NS group (Pearson w 2 (1) ¼ 4.71, P ¼ 0.030) and to have two A alleles at the FREQ rs3780715 SNP (Mantel-Haenszel w 2 (1) ¼ 6.03, P ¼ 0.014). There were no other significant differences in genotype or baseline variables by completion status. A longitudinal logistic regression of abstinence at EOT and 6 months was performed (Table 1) . A significant interaction between FREQ rs1054879 and DRD2 À141 Ins/Del was found (OR ¼ 2.32, 95% CI ¼ (1.13, 4.79); Z ¼ 2.28, P ¼ 0.022). The form of the interaction, based on the bivariate analysis, is illustrated in Figure 1 . There was no evidence from the bivariate analysis for an interaction between the FREQ rs3780715 SNP and DRD2À141. As shown in Table 1 , there was a significant effect of time point, with a lower odds of Variation in DRD2 and FREQ predicts response to NRT abstinence at 6 months compared to EOT. As previously reported, 5 the main effect of DRD2 À141 Ins/Del was also significant. There was no evidence for interacting effects of either FREQ SNP with treatment type. Finally, as previously reported, 5 analyses of 41 random SNPs provided no evidence of population stratification in this sample.
Treatment outcome
We also examined the interaction of the FREQ haplotypes with DRD2À141 in determining outcome using log-linear modeling within the program HAPIPF. The model assumed a saturated interaction between the two FREQ SNPs, DRD2À141 genotype, and outcome. The test was not significant at EOT (likelihood ratio w 2 (9) ¼ 15.07, P ¼ 0.09) or at 6 months (likelihood ratio w 2 (9) ¼ 8.63, P ¼ 0.5). As shown in Table 2 , the DRD2À141 association with outcome appears to be modified only by alleles at the FREQ 1045879 locus. Therefore, the haplotype does not increase outcome prediction above the logistic model.
Discussion
The present study examined the association of variation in the FREQ gene with therapeutic response to NRT for the treatment of nicotine dependence. Consistent with the role of NCS-1 in modulating dopamine D2 receptor signaling, 12 we found evidence for a statistically significant interaction between a common variant in the FREQ gene (rs1054879) and a functional variant in the DRD2 promoter, DRD2 À141 Ins/Del. This finding builds upon our previous report indicating that smokers with at least one copy of the DRD2 À141 Del allele have higher abstinence rates when treated with NRT, 5 and suggests that this enhanced response to treatment is present only for the subset of smokers who also are homozygous for the A allele of FREQ rs1054879; 62% of these smokers were abstinent at EOT compared with abstinence rates of 29-38% among other groups of smokers. This effect is independent of type of NRT and is present (although diminished) at 6-month follow-up, consistent with a pharmacogenetic effect. Because this open-label randomized trial of NRT did not include a placebo arm, it Variation in DRD2 and FREQ predicts response to NRT
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is not possible to determine whether the observed epistatic genetic effect reflects an enhanced ability to quit smoking or response to NRT. It has been previously demonstrated that the Del allele of the DRD2À141 polymorphism reduces the transcriptional activity of the DRD2 promoter, 13 which is expected to lead to a lower density of D2 receptors at nerve terminals. Although the function of the FREQ rs1054879 polymorphism is unknown, the interaction between the D2 dopamine receptor and the NCS-1 protein has been well characterized. In vitro studies have shown that NCS-1 attenuates dopamine-induced D2 receptor desensitization and internalization in a calcium-dependent manner. 12 Genetic variation in the FREQ gene leading to altered NCS-1 protein levels or function would be expected to alter the rate of D2 receptor desensitization and internalization. Because nicotine stimulates dopamine release from striatal neurons, 14 changes in D2 signaling associated with genetic variation in FREQ could modulate liability to relapse and/or response to NRT.
FREQ rs1054879 is located in the terminal exon of the FREQ gene, which encodes the 3 0 untranslated region of the FREQ mRNA. Because the function of FREQ rs1054879 has not been determined, it is possible that FREQ rs1054879 is in tight linkage disequilibrium with a functional SNP in the 3 0 end of the FREQ gene. To investigate the possibility that a functional SNP in FREQ modulates the effects of the DRD2 À141 Ins/Del on smoking cessation treatment outcome, it will be necessary to genotype additional known nonsynonymous SNPs and to identify novel SNPs in the FREQ gene by sequencing the exons and the intron/exon boundaries in the 3 0 end of this gene. In addition, based on the results of this study, it will be important to analyze variation in genes encoding additional DRIPs. One interesting candidate DRIP is the gene encoding G-protein-coupled receptor kinase 2 (ADRBK1), because this enzyme has been shown to interact with both NCS-1 and DRD2 proteins 12 and functions to regulate DRD2 receptor desensitization. 15, 16 It should be noted that we also examined whether the FREQ SNPs modified the effect of the DRD2 À141 Ins/Del on response to bupropion in a placebo-controlled bupropion trial for smoking cessation. 5 In that trial, we found no evidence for an association of the FREQ SNPs with smoking cessation or response to bupropion therapy, or modulation of the DRD2À141 effect. There are several possible explanations for the lack of a FREQ SNP by DRD2À141 interaction in the bupropion trial. First, it is possible that the importance of FREQ (and NCS-1) in modulating D2 signaling and smoking cessation is specific to NRT; that is, the presence of nicotine and resulting effects on dopamine release may be a necessary condition for this effect to be observed. Alternatively, the different results across the two studies may be attributable to differences in demographic backgrounds, ethnic ancestry, or ascertainment between the two study populations, or the present result may be a false positive. 17 Clearly, the present results should be validated in an independent trial of NRT, preferably a placebo-controlled trial in which the genotype effects on smoking cessation can be separated from effects on response to NRT.
The results of the present study should be considered hypothesis generating, and a few limitations in study design should be considered. First, the absence of a placebo control arm precludes determination of whether the observed effect reflects response to nicotine therapy or a general smoking cessation ability. A second limitation of this study is the incomplete coverage of haplotype blocks within the FREQ gene. Given the promising initial evidence for a DRD2 by FREQ interaction, additional investigation of variation across the FREQ gene and identification of potentially functional polymorphisms is warranted. Third, we focused the analysis on smokers of European ancestry in order to limit potential bias due to ethnic admixture. We have shown previously that, in this European ancestry sample, there is no evidence for population substructure that could bias study results. 5 Nonetheless, the use of a homogeneous population prevents us from generalizing the results of this study to nicotine-dependent persons of other ethnicities. To confirm the findings of the present study, additional prospective studies using larger populations of nicotinedependent subjects from multiple ethnic backgrounds are necessary.
Despite these limitations, the present study revealed an intriguing pharmacogenetic interaction between polymorphisms in two genes encoding components of the D2 dopamine receptor signal transduction pathway, DRD2 and FREQ, in a smoking cessation trial with NRT. This finding underscores the importance of examining variation not only in genes encoding neurotransmitter GPCRs, but also in genes encoding proteins that function to regulate intracellular signaling properties of these receptors, such as DRIPs. The results of this study also suggest that genetic variation in DRIPs or other genes encoding proteins that regulate signaling through dopamine receptors may underlie the inconsistent results for DRD2 polymorphisms in casecontrol association studies of the smoking phenotype. 18, 19 The signal transduction pathway-based approach taken in this study should serve as a biological rationale for studying how variation in genes encoding DRIPs impacts both the pathophysiology of, and the response to pharmacological treatments for, other psychiatric disorders that are thought to result, at least in part, from perturbations in dopaminergic neurotransmission including schizophrenia, bipolar disorder, and cocaine dependence.
Materials and methods
Participants and procedures
The present study included 363 current cigarette smokers of European ancestry who were aged X18 years and had smoked at least 10 cigarettes per day for the 12 months prior to study enrollment. These individuals were participants in an open-label randomized clinical trial of two forms of NRT for smoking cessation: TN vs nicotine NS. Exclusion criteria included pregnancy or lactation, uncontrolled hypertension, unstable angina, heart attack or stroke within the past 6 months, current treatment or recent diagnosis of cancer, drug or alcohol dependence, current diagnosis or history of a DSM-IV Axis I psychiatric disorder, and current use of bupropion or nicotine-containing products other than cigarettes.
The details of subject recruitment as well as the design and the results of the clinical trial have been previously reported. 5, 20 Briefly, participants responding to newspaper advertisements were screened for eligibility, completed a pretreatment assessment of demographics and smoking history, and then were randomized to receive either 8 weeks of nicotine NS or 8 weeks of TN patch. Self-report data on smoking status were obtained at EOT and 6-month followup, using a validated timeline follow-back method. 21 Participants who reported complete abstinence (not even a puff of a cigarette) for at least the 7 days prior to the assessment were asked to complete an in-person visit for biochemical verification of abstinence using exhaled carbon monoxide (CO) reading (cotinine verification was not used because the treatments contained nicotine).
This study was approved by the Institutional Review Boards at participating institutions and informed consent was obtained from all participants for both the clinical trial and genetic analysis.
Measures
Genotype. There are no known functional SNPs in the FREQ gene. SNPs were selected using the SNPbrowser 2.0 software (Applied Biosystems Inc.). The three SNPs genotyped (rs3780708, rs3780715, rs1054879) all had minor allele frequencies 40.2 and spanned the gene. Rs3780708 is in the 5 0 end of the first intron, rs3780715 is in the 3 0 end of the first intron, and rs1054879 is in exon 8 (the 3 0 most exon). There is about 27 kb spanning the first two SNPs and 33 kb between the second and third SNPs (haplotype blocks 1, 2, and 6, respectively). Unfortunately, there were a large number of genotype failures for the rs3780708 SNP due to technical reasons relating to the fidelity of the genotyping assay (n ¼ 48); therefore, data are presented for rs3780715 and 1054879.
All genotyping was performed using ABI Assays-onDemand genotyping reagents according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Genotypes were called using the Allelic Discrimination End-Point Analysis function on an ABI Prism s 7300 Sequence Detection System. The accuracy of the FREQ genotypes was insured by including 5% duplicate samples on all genotyping plates. All genotype frequencies were analyzed to ensure that there were no significant deviations from those predicted by Hardy-Weinberg equilibrium.
Covariates. Sex, education, age, and smoking rate were assessed at baseline. Nicotine dependence was also assessed at baseline using the Fagerström Test for Nicotine Dependence. 22 Primary outcome. Abstinence from smoking was assessed at EOT (8 weeks after the target quit date (TQD)) and at 6 months after the TQD. In accordance with recommendations of the SRNT expert panel, 23, 24 participants were classified as abstinent if they self-reported abstinence (not even a puff) for each of the 7 days immediately prior to the follow-up point (i.e., point-prevalence), and provided a CO reading of p10 p.p.m. Consistent with these recommendations, we presumed that those who failed to complete the follow-up, or failed to provide a CO sample for biochemical verification, had relapsed.
Statistical analysis
Descriptive statistics were obtained for all variables in the analyses. w 2 tests and t-tests were used to test differences in baseline variables by treatment assignment and study completion status. w 2 tests were used to test differences in abstinence rates by treatment group and genotype. We also examined associations of FREQ rs3780715 and FREQ rs1054879 genotypes with abstinence separately among cases with different À141C Ins/Del genotypes, to identify possible gene-gene interaction effects. A longitudinal logistic regression of abstinence at EOT and 6 months was performed, using the general effect estimation procedure (XTGEE) in STATA (STATA Corporation, College Station, TX, USA). The SNP genotypes (FREQ rs3780715 and FREQ rs1054879) were treated as ordinal variables (i.e., number of G alleles). The model controlled for covariates (smoking history, sex) and included terms for the following two-way interactions, based on the results of bivariate analysis: treatment group by time point; treatment group by FREQ genotypes; and FREQ rs1054879 genotype by À141 Ins/Del.
Analysis of the two-locus haplotype was performed using the HAPIPF routine in STATA. 25, 26 
